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Abstract
Background: Arthritis secondary to developmental hip dysplasia often mandates implant surgery at a relatively
young age. Hip resurfacing arthroplasty (HRA), compared with standard stemmed total hip arthroplasty (THA),
affords a more active lifestyle including extreme-motion activities but stimulates concerns pertaining to implant
failure.
Methods: We addressed the primary modes of failure through a series of interventions, including a new guideline
for achieving proper implant alignment through intraoperative x-rays. We then compared two sequential cohorts in
a single-surgeon practice: patients with developmental dysplasia who underwent HRA before (Group 1; 121 hips in
105 patients) and after (Group 2; 242 hips in 210 patients) June 2008, at which time the four interventions were all
in place.
Results: Implants in Group 2 failed less frequently within two years (0.8 % vs. 6.6 %, p = 0.002) and were more
likely to have projected seven-year Kaplan-Meier survivorship (99 % vs. 89 %, p < 0.0001 by log-rank test). Patients
in Group 2 were more likely to have normal metal ion levels (77 % vs. 56 %, p = 0.0008) and optimum metal ion
levels (99 % vs. 86 %, p = 0.0008). Patients in Group 2 also benefited from a 19-min decrease in mean operation
time, a 45 % decrease in mean estimated blood loss, and a 0.9-day decrease in mean hospital stay (p < 0.0001 in
each instance).
Conclusions: We believe the interventions reported here, combined with sufficient surgeon experience and
properly designed implants, afford patients with mild developmental dysplasia a more active lifestyle with
favorable implant survival.
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Background
Deformities of the acetabulum and femur make arthritis
due to developmental hip dysplasia a unique challenge
for orthopedic surgeons. The shallow, oval-shaped acet-
abulum complicates proper implant alignment. Increased
tissue laxity motivates many patients with hip dysplasia to
self-elect high range-of-motion (ROM) activities such as
ballet and gymnastics, which then accelerate the develop-
ment of arthritis and increase the likelihood of prosthetic
instability [1, 2] (See List of Abbreviations). Theoretical
advantages of hip resurfacing arthroplasty (HRA) over
standard stemmed total hip arthroplasty (THA) for these
patients include greater hip stability [3–5], less thigh pain
[6, 7], more nearly normal gait [8–10], and resumption of
high ROM activities [11–13]. However, reported failure
rates for both HRA and THA run higher for patients with
dysplasia than in most other patient populations. Failure
rates have been especially high in women who are more
likely than men to have this disorder [11, 14, 15].
We have long suspected that the technical difficulties
of achieving optimum alignment with HRA explain at
least in part the divergent results from registry data. The
Australian joint registry, perhaps the most comprehen-
sive project of its kind, indicates that women under age
60 experience higher failure rates with HRA than with
THA, while the reverse holds for men [14, 16, 17]. On* Correspondence: dani.gaillard@midlandsortho.com
Midlands Orthopaedics & Neurosurgery PA, 1910 Blanding Street, Columbia, SC, USA
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gaillard and Gross BMC Musculoskeletal Disorders  (2016) 17:251 
DOI 10.1186/s12891-016-1095-7
the basis of these and similar data, many professionals
advise against HRA for younger women. Paradoxically,
experts do not advise against THA for younger men des-
pite their reported lower failure rates with HRA. The
greater technical difficulty of HRA compared to THA
possibly explains this inconsistency. With THA, amputa-
tion of the femoral neck allows the surgeon to achieve
better exposure while with HRA, preservation of the
femoral head makes acetabular preparation a technical
challenge and a barrier to better results and wider ac-
ceptance of this procedure [18, 19].
We have sought to identify principal causes of failure
and to develop strategies to eliminate each failure mode.
In patients with development dysplasia, we previously de-
termined [20] the main causes of revision to be the failure
of acetabular ingrowth (FAI) and adverse wear related
failure (AWRF). In contrast to other reports [1, 9], we did
not find early femoral failure (EFF) to be more common
in dysplasia patients. We therefore focused mainly on de-
veloping strategies to prevent FAI and AWRF, while not
ignoring EFF. We also developed an uncemented femoral
component with the aim of reducing the 3 % rate of late
loosening of the cemented femoral component that oc-
curred in our resurfacing cases [3, 21].
In this paper, we describe four specific strategies (in-
terventions) and their combined impact on outcomes
of HRA for arthritis secondary to developmental dys-
plasia of the hip. These consist of improved acetabular
component fixation to address FAI, including use of the
Magnum™ Tri-Spike component in higher-risk cases
with the largest deformities; improved acetabular com-
ponent alignment, intended to prevent AWRF, through
a better understanding of optimum positions and ways
to obtain them, notably use of a normalized intraopera-
tive x-ray technique as well as use of a new guideline
for component alignment (see Materials and Methods);
a bone protection program, designed to prevent EFF,
based on modified early weight-bearing and alendro-
nate with emphasis on individual patients’ bone density
femoral neck T-scores and body mass indices (BMI);
and uncemented femoral fixation, intended to reduce
the rates of EFF and early femoral loosening. We ana-
lyzed the impact of these strategies by comparing two
sequential cohorts of patients undergoing HRA for de-
velopmental dysplasia: one before, and one after, all of
these interventions were in place.
Methods
Patients and follow-up
The senior author has maintained a prospective data-
base of more than 4200 HRA procedures, of which 518
(12 %) have been in patients with underlying dysplasia.
Procedures were performed at Providence Northeast
Hospital, Lexington Medical Center, and Midlands
Orthopaedics Surgery Center, all located in Columbia,
SC. The database has a 96 % overall follow-up rate.
The present analysis includes 121 HRA procedures for
dysplasia performed between January 2001 and July
2008 (Group 1) and 242 procedures performed be-
tween August 2008 and July 2013 (Group 2), all with
minimum 2-year follow-up. Approvals for this study
and report were obtained from the Institutional Review
Board of Sisters of Charity Providence Hospitals,
Columbia, South Carolina.
Patients are born with varying amounts of ovoid de-
formity and erosion gradually increases their dysplasia
grade. Degree of dysplasia was graded as follows: Grade
1, 50 % to 80 % coverage of the femoral head on stand-
ing anterior posterior (AP) x-ray, with less than 1 cm of
superior migration; Grade 2, less than 50 % coverage,
but less than 2 cm of superior migration; Grade 3, more
than 2 cm of superior migration of the head, irrespective
of coverage; Grade 4, superior migration with a false
acetabulum; and Dysplasia with Osteotomy, deformity by
previous femoral and/or acetabular osteotomy. Osteo-
phytes are excluded when judging coverage. Most pa-
tients with dysplasia inexorably progress to higher
grades as relentless bone wear elongates the socket and
subluxes the femoral head into the superior aspect of
the oval defect, from which it eventually migrates out of
the socket. We characterize socket anteversion as an
oval acetabulum. Preoperative AP pelvic x-rays demon-
strate variable amounts of head coverage and superior
migration. Intraoperatively, all patients are found to have
oval sockets (osteoarthritic sockets with eccentric bone
wear excluded).
Implant systems
The senior author used three separate implant systems
in a consecutive fashion. Beginning in March 2001, Hy-
brid Corin Cormet 2000 (Corin, Cirencester, UK) devices
were employed as part of a multicenter United States
Food and Drug Administration trial. Beginning in 2005,
Biomet (Biomet, Warsaw, Indiana) devices comprised of
a cemented ReCap™ femoral component and an unce-
mented Magnum™ acetabular component were used. Be-
ginning in 2007, we initiated the use of completely
uncemented Biomet ReCap™ Magnum™ devices, with the
Magnum™ Tri-Spike component used in higher-risk pa-
tients with the largest deformities. Currently, all devices
are uncemented. Using these Biomet devices in the pro-
cedure reported here falls under the category of off-label
use in the United States.
Procedure
This study spans a period of 11 years during which
surgical technique evolved. A summary of surgical infor-
mation from these cases is listed in Table 1. Over time,
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we recognized several key features in dysplasia patients:
The acetabulum is always oval to a varying degree,
which is present at birth and increases as the hip wears.
The long axis of the oval is always from posterior infer-
ior to anterior superior. The head rides into the superior
corner of the oval and then begins to sublux. The thick-
est bone for placing the cup is posterior inferior. The
cup is shallow, and medial wall thickness is variable
(Fig. 3a). These patients exhibit hypermobility and are
prone to dynamic posterior pelvic tilt on standing. The
transverse acetabular ligament (TAL) is an excellent ref-
erence point for judging correct anteversion.
DeSmet [22] demonstrated that steeper, more ante-
verted components were problematic especially in dys-
plasia patients with smaller bearing sizes (34 % patients
in this study had bearing size < 48 mm). He defined the
useful concept of coverage arc, which depends largely on
the design features of the implant and its proper surgical
positioning. We further developed this concept with the
Relative Acetabular Inclination Limit (RAIL) guideline
[23] (Fig. 1) for placing components based on bearing
size. The RAIL dictates an acetabular inclination angle
(AIA) limit on a standing AP pelvis x-ray that is different
for each bearing size. We placed an arbitrary lower AIA
limit of 25° on the guideline. We next developed a tech-
nique to obtain an intraoperative x-ray that was normal-
ized to the standing position (unpublished). These
techniques were fully established by mid-2008.
All operations were performed by a single surgeon
(TPG). Cemented femoral components were implanted
using small amounts of high-viscosity cement on both
the bone and implant surfaces with an escape trough
machined into the femoral head. In Group 2, stems were
never cemented.
The posterior approach used in these cases was de-
scribed previously [24]. A 4- to 6- in. skin incision is
made; the gluteus maximus, quadratus femoris, and all 3
short rotators are released off of the bone and are subse-
quently repaired, the conjoined tendon is incised 1–
2 cm, a neck-sparing complete capsular division and re-
pair is performed. A pocket is created under the mini-
mus for later placement of the head.
The head is first prepared. Typically, it is oval and
foreshortened. Therefore, more is typically trimmed
from the periphery than from the apex. The neck gauge
is applied to measure the smallest femoral component
Table 1 Demographics
Pre-2008, Group 1 (N = 121) Post-2008, Group 2 (N = 242) P-value
Sex (no. of hips)
MALE 35 (29 %) 64 (26 %) 0.6171
FEMALE 86 (71 %) 178 (74 %)
DECEASEDa 3 (2.5 %) 1 (0.4 %) 0.0751
Follow-up Mean Years 6.4 ± 2.31 2.6 ± 1.51 <0.0001b
Case Date Range 1/2001–7/2008 7/2008–7/2013 –
Age (yr) 48 ± 8.37 52 ± 7.05 <0.0001b
BMI 26 ± 5.04 26 ± 5.08 1.000
T-score −0.34 ± 1.44 −0.40 ± 1.10 0.6599
Overall Failures (no. of hips) 16 (13.2 %) 2 (0.8 %) <0.0001b
2-Year Raw Failures (no. of hips) 8 (6.6 %) 2 (0.8 %) 0.0015b
7-Year Survivorship (no. of hips) 108 (89.3 %) 240 (99.2 %) <0.0001b
Dysplasia Grade (no. of hips)
Dysplasia I 37/51 (73 %) 188/241 (78 %) 0.4009
Dysplasia II 10/51 (20 %) 49/241 (20 %) 0.9045
Dysplasia III 0/51 (0 %) 0/241 (0 %) 1.000
Dysplasia IV 0/51 (0 %) 0/241 (0 %) 1.000
Dysplasia Osteotomy 4/51 (7.8 %) 4/241 (1.7 %) 0.0139b
Grade Unrecorded 70/121 (58 %) 1/242 (0.4 %) <0.0001b
ASA Score 1.6 ± 0.55 1.6 ± 0.56 1.000
Femoral Component <48 mm (no. of hips) 46/121 (38 %) 79/242 (33 %) 0.3077
Femoral Component Size 48.1 ± 3.45 47.0 ± 2.91 0.0016b
aDied with the causes unrelated to their hip arthroplasties
bStatistically significant
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possible. The central guidewire is placed. Although it is
not critical, we attempt to place the stem neutral down
the center of the neck and parallel to the calcar. There is
no way to alter femoral version, and we are of the opin-
ion that it does not matter. We have never found the
need for a femoral derotation osteotomy. The head is
then typically cut 6 mm (3 sizes) larger than the smallest
component possible (neck gauge). If there is doubt, we
cut one size larger (2 mm) and later come back and trim
it down if necessary after the acetabulum is implanted.
The trial head is placed and the head is then tucked into
the pocket under the minimus and held with a double-
angled Hohmann retractor.
The thickened labrum is excised except for a small
band in the anterior inferior region against the psoas.
The TAL must be preserved during this maneuver, be-
cause it is the best guide for anteversion. We find it a re-
liable guide even in the face of the acetabular deformity.
The reamer equal to the prepared head size is used first.
It is inserted at a 45° angle with the floor but pulled
firmly inferiorly and posteriorly while pushing centrally
(Fig. 3b). It is forced to progress into the thick posterior
wall and down to the quadrilateral plate. If the surgeon
is not careful and allows the reamer to seat anterior su-
perior (AS) into the oval defect while reaming, the entire
preparation is incorrect and cannot be salvaged. This
cannot be overemphasized. This initial preparation
serves several purposes. First, the cavity is prepared in
the thicker posterior bone. Second, the anterior inferior
(AI) bone adjacent to the psoas is preserved. Third, the
center of rotation is corrected in high-riding cases. The
medial wall is then drilled at the superior edge of the
fovea and a depth gauge is used to measure the medial
wall. For proper cup coverage, the cavity can be media-
lized until 6 mm remains medially. As soon as the
optimum medial position has been achieved, larger
reamers are used to expand the cavity (Fig. 3c). The
reamer handle is still firmly held posteriorly and infer-
iorly, but the grip is slightly loosened to allow the
reamer to progress slightly into the oval defect AS. A
line-to-line reaming is performed if the dual energy x-
ray absorptiometry (DEXA) T-score exceeds −1.0 (good
bone). A 1-mm under-reaming is employed when the T-
score falls below −1.0 (soft bone) (T-score is a reference
to gender and race specific bone density in a healthy,
young 25-year old [25]; a normal T-score is from 1 to
−1). A clean reamer 1 mm larger than the head size is
then used to deepen the apex of the cavity by 1–2 mm.
This prevents the cup from bottoming out at the apex of
the cavity and instead creates a wedge fit on the rim.
The trial is placed and aligned with the TAL with an
AIA dictated by the RAIL guideline. If a significant
amount of the oval defect remains such that 30 % or
more of the component wall is uncovered (Fig. 3d), a
Tri-Spike component (Fig. 4) is chosen. If the preopera-
tive T-score is less than −2.5, a Tri-Spike is also chosen.
Otherwise, a standard Magnum™ cup is used. Approxi-
mately 5 % of these cases required a Tri-Spike compo-
nent since it became available. The trial is used to
determine if three criteria are met: AIA is within RAIL
guidelines, anteversion is parallel to the TAL, and the
cup edge is below the bone edge in the AI corner adja-
cent to the psoas. If these criteria are not met, the cavity
typically needs to be deepened slightly to allow the trial
to satisfy these conditions. After assuring the trial cri-
teria are met, the cup, which is hemispherical with a
rough titanium plasma spray coating and 4 sharp fins, is
lightly impacted into the prepared cavity with a curved
inserter. The position is then finely tuned with a plastic
tip tamp and mallet. If the cup needs to be removed, a
metal tip tamp is used on the exposed edge. When the
position is correct, a secondary impactor designed to
Fig. 1 RAIL Reference Table. RAIL guideline for correct acetabular component placement to avoid high ion levels and AWRF in HRA. The lower
limit is arbitrarily set at 25°, the upper limit of acceptable AIA is listed for each bearing size. For the smallest bearing size (40 mm) there is only a
7° window, making placement very challenging
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ride over the edge of the cup is used for a final impac-
tion with a large mallet. If a Tri-Spike component is
used, repositioning requires removal; technically, these
are more difficult to orient perfectly according to the
above criteria.
The head is trimmed if necessary to match the ace-
tabular component. The Magnum™ cup outer diameter
is 6 mm larger than the head/bearing size. All cysts are
curetted and grafted. The ReCap™ component is im-
pacted until sonic change indicates that it is fully
seated. The hip is reduced and an x-ray is obtained.
Closure is routine, repairing all structures anatomically
in multiple layers.
Normalized to standing intraoperative x-ray
The normalized intraoperative x-ray technique (fully-de-
veloped by mid-2008) utilizes a portable, digital x-ray
machine that enables immediate comparison of an image
taken in the operating room (OR) with the patient’s pre-
operative standing x-ray. After the acetabular compo-
nent is implanted according to the technique described
previously [24], the OR table is rotated until the surgeon
judges the pelvis to be neutral. The first film is taken.
The surgeon inspects the width of the obturator foram-
ina on the image and then asks the anesthetist to roll
the table right or left to correct for any rotation. Films
are repeated until the widths of the obturator foramina
are symmetrical. The surgeon then compares the height
of the obturator foramina to the height seen on the pre-
operative standing AP pelvis x-ray. The x-ray machine is
tilted cephalad or caudad and films are repeated until
the obturator foramina and the pelvic inlet appear as
they do on the preoperative standing AP pelvis x-ray.
Thus, the end result is an intraoperative image of the
pelvis normalized to the patient’s preoperative standing
position. This image is sent to the desktop computer in
the OR and the AIA is measured. If the AIA does not
meet RAIL criteria (Fig. 4), the cup is repositioned and
another x-ray is obtained. With practice, this process
typically takes less than 2 min, and less than 5 % of cups
need repositioning.
Postoperative protocol
We previously concluded that the risk of EFF (early fem-
oral failure: femoral neck fracture and collapse) depends
largely on two factors: bone density (femoral neck T-
score) and BMI [26]. Our bone management protocol
establishes three groups based on these risk factors:
Group A, femoral neck T-score score > 0 and BMI < 30;
Group B, femoral neck T-score between 0 and −1.5 and/
or BMI > 30; and Group C, femoral neck T-score < −1.5.
Group A patients are allowed to progress weight-
bearing as tolerated (WBAT). They typically use
crutches for 1–2 weeks and a cane for 1–2 weeks. Group
B patients are also allowed WBAT but are prescribed
alendronate for 6 months. Patients from Group C or any
patients who require a Tri-Spike cup are placed on a
slowed weight-bearing protocol and are prescribed alen-
dronate for 1 year. They are asked to do 10 % weight-
bearing for 4 weeks, WBAT with crutches for 2 weeks,
and a cane for another 4 weeks. Isometric leg lifts, light
aerobic activity (such as exercise bike and swimming),
lower extremity weight lifting less than 50 lb, golf, and
unrestricted walking is encouraged at 6 weeks for
Groups A and B and at 10 weeks for Group C patients.
All restrictions in all patients are lifted at 6 months, and
they are encouraged to participate in full-impact sports.
No formal physical therapy is requested of the patient
after hospital discharge.
Deep vein thrombosis precautions include sequential
compression devices started intraoperatively and discon-
tinued at the time of hospital discharge. Ambulation and
leg exercises are started within 24 h. Oral anticoagulants
are started at 24 h postoperative and continued for 2–4
weeks, depending on risk analysis. Then, 81 mg aspirin
is recommended for another month.
A multimodal pain management protocol and a com-
prehensive blood management protocol are used to
eliminate transfusion and speed recovery. In the last 3
years, resurfacing has been performed as an outpatient
procedure on selected patients.
Metal ion testing
Our database contains blood, serum, and plasma ion
levels for these cases. We used the method of Smolders
[27, 28] to convert all serum and plasma levels to whole
blood levels, and thus, we used blood levels for all com-
parisons. DeSmet and colleagues [22] demonstrated that
blood ion levels provide an excellent surrogate marker,
or screening tool, for wear and are thus useful for
screening for AWRF prior to the onset of any symptoms.
We define 5 different ion level categories based on pre-
vious research [22, 23, 27, 28]: normal, optimal, accept-
able, problematic, and potentially toxic. These reference
ion values are shown in Table 2.
Clinical and radiological analysis
Office or remote follow-up was requested at 6 weeks, 1
and 2 years, and every other year thereafter. A clinical
questionnaire, radiographs, and a physical examination
testing ROM and strength were performed at each visit.
After 1 year, physical examinations were no longer
done routinely on remote follow-ups. The OrthoTrack
database (Midlands Orthopaedics, Columbia, South
Carolina) supported our collection and analysis of the
demographic, clinical, and radiographic data for all
patients.
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Patient questionnaires requested information neces-
sary to calculate the following scores for clinical evalu-
ation: Harris hip score (HHS) [29], University of
California, Los Angeles (UCLA) activity score [30], and
visual analog scale (VAS) pain score for normal and
worst days [31]. HHS determines clinical outcome;
UCLA activity scores measure activity level after surgery
on a scale from 1 to 10, for which 10 represented the
highest level of activity; VAS pain scores rate the level of
pain from 0 to 10, with zero representing no pain and
10 representing maximum levels of debilitating pain.
Both supine and standing AP pelvis and lateral radio-
graphs are taken and analyzed for component position,
shifting, and radiolucencies by the senior author. The
AIA is determined by measuring the angle formed be-
tween 2 straight lines: one running across the face of the
acetabular component and the other across the inferior
pubic rami (Fig. 2). All measurements were performed
using OrthoTrack (Midlands Orthopaedics).
Statistical methods
The significance level α was defined as 0.05 for all statis-
tical analyses in this study. A paired, 2-tailed T-test was
used to calculate the significant difference between pre-
operative and postoperative numerical outcomes within
and between dysplasia study groups; the Student’s T-test
was used to compare the difference of numeric variables
between groups. When comparing two population pro-
portions, a two-sample Z-test was used. Statistical tests
were performed using SAS (Cary, NC). Kaplan-Meier
survivorship curves were plotted to evaluate implant
survival among different groups. Log-rank and Wilcoxon
tests were performed to calculate significant differences
between survivorship curves. Curves and survivorship
statistical tests were generated using XLSTAT (New
York, NY).
Results
Groups 1 and 2 were demographically similar, although
patients enrolled subsequent to mid-2008 (Group 2)
tended to be slightly older and less likely to have had
dysplasia with a prior osteotomy (Table 1). Patients in
Group 2 had significantly shorter operation times (mean
95 min versus 114 min in Group 1, p < 0.0001), signifi-
cantly less estimated blood loss (mean 142 mL versus
257 mL in Group 1, p < 0.0001), and significantly shorter
hospital stays (mean 1.7 day versus 2.6 days, p < 0.0001)
(Table 3). UCLA scores and VAS scores were better in
Group 2 than in Group 1 (UCLA p = 0.0006, VAS Regu-
lar p = 0.005, VAS Worst p < 0.0001); however HHS and
combined ROM were unchanged (Table 4).
Radiographic data (Table 4) indicated that acetabular
components were placed in a more closed position after
implementation of the RAIL guideline (Fig. 1) and the
normalized x-ray technique (AIA 35° versus 41° for
Group 2 and Group 1, respectively, p < 0.0001). Retro-
spective analysis indicated 28 (24 %) patients in Group 1
had nonideal AIA according to the RAIL criteria; 6 of
these patients (25 %) had problematic ion levels and 4
patients (17 %) developed AWRF. After implementation
of the RAIL guideline, only 3 patients (1 %) had nonideal
AIA and none had AWRF or problematic ion levels.
These cases were done in December 2008, January 2009,
and March 2011; on follow-up, all of these patients have
Table 2 Metal ion reference values
Normala Optimalb Acceptablec Problematicc Potentially Toxicb
Unilateral
• Co <1.5 μg/L <4.0 μg/L 4–10 μg/L 10–20 μg/L >20 μg/L
• Cr <1.5 μg/L <4.6 μg/L 4.6–10 μg/L 10–20 μg/L >20 μg/L
Bilateral
• Co <1.5 μg/L <5.0 μg/L 5–10 μg/L 10–20 μg/L >20 μg/L
• Cr <1.5 μg/L <7.4 μg/L 7.4–10 μg/L 10–20 μg/L >20 μg/L
alaboratory normal for patients without metal bearings
baccording to DeSmet /van der Straeten
caccording to our previous analysis
Fig. 2 Radiograph Measurement References. Anterior-posterior
pelvis radiograph made five years after a hybrid metal-on-metal
Corin hip resurfacing on the right hip and two years after a hybrid
metal-on-metal Biomet ReCap™ hip resurfacing on the left hip. Better
AIA is noted in the most recent HRA on the patients left side
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had normal ion levels and HHS = 100. Since March
2011, no patients have failed to meet RAIL criteria.
Patients in Group 2 had lower mean metal ion levels
and were more likely to have normal (p = 0.005 for uni-
lateral and p = 0.05 for bilateral cases) and optimal ion
levels (p = 0.0003 for unilateral and p = 0.04 for bilateral
cases) (Table 5). Cobalt levels in the 242 consecutive
high-risk dysplasia patients in Group 2, of whom 70 %
were women and 34 % required bearing sizes < 48 mm,
were optimal in 99 % of unilateral cases and 88 % of
Fig. 3 Dysplasia technique. a The typical oval dysplasia deformity is illustrated. b Initial reaming is demonstrated. c Reamers are gradually expanded
to capture oval defect. d Cup stability is judged by amount of trial that remains uncovered anterior-superiorly
Fig. 4 ReCap™ Components. a Tri-Spike Magnum™ component used if less than 70 % cup coverage is achieved. b Uncemented Biomet ReCap™
femoral component
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bilateral cases, with no levels > 10 μg/L. All patients with
AWRF in Group 1 had ion levels ≥ 15 μg/L. To date, 4
patients in Group 1, but none in Group 2, have devel-
oped AWRF (p = 0.01) (Table 6).
Patients in Group 2, by definition, have had shorter
durations of follow-up than those in Group 1. However,
all patients in Group 2 have had at least 2 years of
follow-up, and some have had 7 years of follow-up. At
2 years, there were 8 implant failures in Group 1 versus
2 in Group 2 (6.6 % vs. 0.8 %, p = 0.002). Seven-year
Kaplan-Meier implant survivorship was higher in Group
2 (99 % vs. 89 %, p < 0.0001) (Figs. 5 and 6). Failures due
to FAI or head collapse have not occurred in Group 2
(Tables 6 and 7). Complications and reoperations are re-
ported in Table 8.
One patient in each group had a single dislocation
from extreme movements; these patients did not require
reoperation or revision for hip instability. Seven patients
in Group 1 and six in Group 2 have had 3D studies to
evaluate residual pain and none have indicated AWRF.
Only two patients in Group 2 (0.8 %) have thus far
required revision. A 60-year-old woman with a BMI
of 24 and a femoral neck T-score of −0.5 had no
intraoperative complications but suffered a femoral neck
fracture 4 days postoperatively and was converted to a
large metal bearing THA without further problems. A 62-
year-old woman with an AIA = 34° on standing pelvis film
on postoperative day one was recovering well but was
found to have an AIA = 17° on her 6-week follow-up
standing AP pelvis x-ray. The well-fixed but malpositioned
cup was revised to a Magnum™ Tri-Spike of the same size
with subsequent excellent outcome.
Discussion
The 363 consecutive implants for mild developmental
hip dysplasia reported here, performed by a single sur-
geon with a 96 % follow-up, represent to our knowledge
the largest reported series on operative treatment for
this condition. The usual limitations of sequential cohort
design apply to this study. Since the two groups (cases
done before and after mid-2008) were not concurrent,
gradual improvements in proficiency in both operative
and perioperative techniques could have come into play.
Lengths of follow-up were, by definition, shorter in
Group 2 (cases done after mid-2008) than in Group 1,
although we note that all patients from either group had
at least 2 years of follow-up. We identified the most
common failure modes for HRA (FAI, AWRF, and EFF)
and addressed these causes through a series of interven-
tions: improved acetabular component fixation, improved
acetabular component alignment through use of the RAIL
guideline based on normalized-to-standing intraoperative
x-rays, a bone protection program based on each patient’s
bone density and BMI, and uncemented femoral fixation.
Patients who underwent HRA for developmental dysplasia
after these interventions were in place showed improved
two-year failure rates, improved projected 7-year Kaplan-
Meier implant survivorships, lower blood ion levels, and
better functional results as assessed by UCLA and VAS
scores (despite unchanged HHSs).
The heterogeneity of the previously-reported case
series of implant surgery for developmental dysplasia
complicates comparison of these data with previously-
reported studies, most of which focused mainly on grade
4 dysplasia or contained mixtures of all grades. Few
studies have limited cases to dysplasia grade 1 and 2,
which are amendable to resurfacing. Millis demonstrated
a 74 % 10-year success rate with the Bernese osteotomy
presumably for low-grade dysplasia [32]. Reports on
cemented THA indicate 73 % to 98 % 5- to 10-year sur-
vivorships [33, 34]; reports on HRA indicate 92 % to
98 % 5- to 10-year survivorships [34, 35]. We are un-
aware of mid-term data for uncemented THA in mild
dysplasia. Implant survivorship in our 242 patients who
had surgery after interventions were all in place com-
pares favorably with previous studies for both THA and
HRA (Table 9).
Table 4 Clinical outcomes
Variable Group 1 Group 2 P-value
Preoperative
HHS Scorea 53 ± 12.44 57 ± 14.91 0.0115*
Postoperative
HHS Score 98 ± 4.10 98 ± 5.49 1.000
UCLA Score 6.3 ± 1.24 7.0 ± 2.05 0.0006*
VASb Pain: Regular 0.5 ± 0.90 0.2 ± 0.98 0.0050*
VAS Pain: Worst day 2.3 ± 2.34 1.2 ± 2.17 <0.0001*
Combined ROMc 289 ± 49.5 291 ± 55.5 0.7376
Radiographic Data
AIAd 46 ± 8.03 34 ± 5.36 <0.0001*
Met RAIL Criteria (# Hips, %) 93 (76 %) 239 (99 %) <0.0001*
Radiolucency (# Hips, %) 2 (1.7 %) 0 (0 %) 0.0444*
Osteolysis (# Hips, %) 0 (0 %) 0 (0 %) 1.000
aHHS - Harris Hip Score
bVAS – Visual Analog Scale
cROM – Range of Motion
dAIA - Acetabular Inclination Angle
*Statistically significant
Table 3 Surgical data
Variable Group 1 Group 2 P-value
Length of Incision (in) 4.5 ± 2.63 4.2 ± 0.49 0.0866
Operation Time (min) 114 ± 18.54 95 ± 14.17 <0.0001a
Estimated Blood Loss (mL) 257 ± 100.07 142 ± 76.60 <0.0001a
Hospital Stay (days) 2.6 ± 1.02 1.7 ± 0.75 <0.0001a
aStatistically significant
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Acetabular component fixation
FAI, the most common failure mode of arthroplasty
for hip dysplasia, occurred mainly in patients with
more severely-elongated sockets. Prior to 2007, inad-
equate supplemental fixation was the usual cause of
FAI in cases where very ovoid or flattened sockets
could not be made hemispherical [20]. In 2007, Bio-
met released a socket with supplemental fixation
(Magnum™ Tri-Spike) that could be employed for re-
surfacing. We subsequently began using this implant
in all cases where > 30 % of implant uncoverage was
judged to exist. Selectively using this implant in only
5 % of severe cases allowed us to eliminate FAI as a
failure mode.
Acetabular component alignment
AWRF, the second-most-common failure mode of im-
plant surgery for dysplasia, results largely from subopti-
mal implant design and alignment. Some authors have
suggested (without evidence) that this failure mode is a
random event related to metal allergy [36]. DeSmet [22]
demonstrated that inadequate functional coverage arc of
the implanted acetabular component is the underlying
cause of excessive metal wear; overwhelming data now
confirms his concepts [37–39]. Inadequate functional
coverage, which results in edge loading, loss of fluid film
lubrication, and an extremely high wear rate, is caused
by suboptimal implant design and unsatisfactory surgeon
placement. Inadequate functional coverage and subopti-
mal alignment lead to excessive metal debris deposition
in tissues, causing an inflammatory reaction, which
we have called AWRF. The logical conclusion from
DeSmet’s work is that AWRF can be avoided in three
ways: select against patients requiring smaller bearing
sizes (mostly women), redesign acetabular compo-
nents to increase coverage arc across all sizes (Wright
Conserve Biofoam component), or learn to consist-
ently implant smaller sizes more horizontally to avoid
edge loading [23]. Herein, we demonstrate the efficacy
of the third option.
The DePuy ASR had a lower coverage arc than all
other designs and was therefore very prone to AWRF.
All current designs (except the new Conserve Biofoam
170°) have coverage arcs that increase with bearing size
(e.g. Biomet Magnum™ varies from 40-mm bearing with
156°, to 60-mm bearing with 164°). Therefore, smaller
bearing sizes in all brands are more prone to AWRF,
leading to females being more susceptible to this mode
Table 6 Failures requiring revision
Type Group 1 Group 2 P-value
# Cases 121 242 –
Acetabular Failures
Adverse Wear 4 (3.3 %) 0 (0 %) 0.0045*
Loose Acetabular Component 1 (0.8 %) 0 (0 %) 0.1556
Failure of Acetabular Ingrowth 6 (5.0 %) 0 (0 %) 0.0005*
Acetabular Component Shift 0 (0 %) 1 (0.4 %) 0.4777
Femoral Failures
Femoral Neck Fracture 1 (0.8 %) 1 (0.4 %) 0.6171
Femoral Head Collapse 2 (1.7 %) 0 (0 %) 0.0444*
Loose Femoral Component 1 (0.8 %) 0 (0 %) 0.1556
Other Failures
Unexplained Pain 1 (0.8 %) 0 (0 %) 0.1556
TOTAL FAILURES 16 (13.2 %) 2 (0.8 %) <0.0001*
astericks indicate statistical significance
Table 5 Metal ion data









P-value Unilat I vs II Bilat I vs II
Coa (μg/L) 1.7 ± 1.90 3.1 ± 2.32 0.0013b 1.3 ± 0.93 2.2 ± 1.33 <0.0001b 0.0679 0.0076b
Cra (μg/L) 1.6 ± 2.15 2.5 ± 2.04 0.0235b 1.2 ± 1.10 1.9 ± 1.67 0.0006b 0.1107 0.0775
Follow-Up Date (Yrs) 5.4 ± 1.93 6.5 ± 2.24 0.0095b 2.2 ± 1.14 2.5 ± 1.16 0.0821 <0.0001b <0.0001b
#, % Patients Tested 105 (87 %) – 187 (77 %) – 0.0316b
#, % Levels Converted 17 (33 %) 21 (42 %) 0.3320 26 (22 %) 19 (25 %) 0.5961 0.1416 0.0510
#, % Revised (Excluded) 15 (12 %) 6 (5 %) 0.0394b 2 (0.8 %) 0 (0 %) 0.1556 <0.0001b 0.0005b
#, % Revised AWRF (Excluded) 2 (1.7 %) 2 (1.7 %) 1.000 0 (0 %) 0 (0 %) 1.000 0.0444b 0.0444b
Normal (#, %) 32 (56 %) 6 (12.5 %) <0.0001b 86 (77 %) 20 (28 %) <0.0001b 0.0058b 0.0466b
Optimal (#, %) 49 (86 %) 35 (73 %) 0.0949 111 (99 %) 63 (88 %) 0.0007b 0.0003b 0.0434b
Acceptable (#,%) 7 (12.3 %) 12 (25 %) 0.0910 3 (2.7 %) 9 (12.5 %) 0.0085b 0.0124b 0.0767
Problematic (#, %) 1 (1.8 %) 1 (2.1 %) 0.9045 0 (0 %) 0 (0 %) 1.000 0.1585 0.2187
Potentially Toxic (#, %) 0 (0 %) 0 (0 %) 1.000 0 (0 %) 0 (0 %) 1.000 1.000 1.000
aCo – Cobalt, Cr - Chromium
bStatistically significant
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of failure (women require a mean bearing size of 46 mm
while men need a mean of 52 mm, in our experience).
We confirm DeSmet’s hypothesis [22] by demonstrat-
ing that implants placed by RAIL criteria (a safe zone
for implanting HRA components based on bearing size)
avoid high ion levels [23] (Fig. 1). To sum, smaller sizes
necessitate a more horizontal position. No metal ion
levels > 10 μg/L or instances of AWRF occurred when
component positions met our RAIL. By mid-2008, we
established intraoperative x-ray techniques [40] to reli-
ably place acetabular components within the RAIL
guidelines, and to date have observed neither edge-
loading nor AWRF in this high-risk population. In a pre-
vious study [39], we had no recurrences of AWRF after
revision. Our implant survival for 58 HRA revisions
(mean patient age = 50 years) was 97 % at a mean of
5 years. Fear of the consequences of AWRF has been
the primary reason that the use of resurfacing has
declined. In this study, we have shown that AWRF is
completely preventable by proper acetabular compo-
nent positioning, and previously, we have shown
that revision surgery, when done correctly, results in
excellent outcomes.
Bone protection program and uncemented fixation
EFF, the third principal failure mode of implants in dys-
plasia patients, correlates with low bone density and
high BMI, as we demonstrated by multivariate analysis
previously [26]. At the same time, we showed that a
bone management program consisting of restricted
weight-bearing and alendronate could eliminate these
failures in high-risk patients. We subsequently expanded
this protocol to include intermediate-risk patients. Add-
itionally, we began using an uncemented Biomet ReCap™
femoral component for resurfacing in 2007 with hopes
of reducing femoral failure modes. Since 2008, they have
been used exclusively. While the early outcomes have
been excellent [4], and the failure rate in osteonecrosis
(ON) cases has been reduced [41], we have not previ-
ously noticed a lower EFF rate with the uncemented
femoral component [26]. In this study, the EFF rate was
reduced for Group 2, but based on these results, we
cannot attribute this improvement to one particular
intervention. Based on our previous studies, we demon-
strated that EFF reduction was primarily due to our
bone management program rather than the uncemented
femoral component.
We are able to show unequivocally that results have
improved; we are also able to show that certain failure
modes are now less prevalent. But because numerous
changes were made, we cannot with certainty under-
stand the exact interplay between variables. There was
no single, clear transition date where all improvements
were simultaneously initiated; rather, they were gradually
developed and instituted in a continual improvement
process. Future studies using regression analyses may be
Fig. 5 Kaplan-Meier Implant Survivorship Curve for Two Study Groups. Kaplan-Meier survivorship curves for pre-2008 (Group 1) and post-2008
(Group 2) resurfacing procedures on dysplasia patients. Revision of any component was used as endpoint. Plus signs represent censored deaths
unrelated to the patient’s hip surgery. (*statistically significant)
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helpful in determining relationships. Next, we currently
lack substantial data on patients with advanced dyspla-
sia, but these results provide excellent insight into mild
cases of dysplasia. We also note the current limitation
of external validity due to the nature of the single-
surgeon study design. Direct comparison of the two
groups was difficult because they were not concur-
rent; however, all patients had a minimum of 2 years
follow-up; therefore, comparison of failures by 2 years
was valid.
The strengths of this study far outweigh the limita-
tions. This investigation was based on detailed, prospect-
ively collected data on consecutive patients. The follow-
up rate was 96 %. Failures that were revised elsewhere
were also recorded. Major changes in our technique
were carefully documented in our database. Lastly, the
demographics of the patients had minimal variation over
time, allowing for more direct comparisons.
Conclusions
A substantial body of literature suggests that HRA,
compared with THA, provides favorable outcomes in
such areas as hip stability, gait, and activity tolerance
Table 8 Complications and reoperations
Type Group 1 Group 2 P-value
# Cases 121 242 –
Complications
Acetabular Complications
Acetabular Component Shift 1 (0.8 %) 1 (0.4 %) 0.6171
Other Complications
Psoas Tendonitis 1 (0.8 %) 0 (0 %) 0.1556
Hip Dislocation 1 (0.8 %) 1 (0.4 %) 0.6171
Abductor Tear 1 (0.8 %) 0 (0 %) 0.1556
Deep Vein Thrombosis 0 (0 %) 1 (0.4 %) 0.4777
TOTAL COMPLICATIONS 4 (3.3 %) 3 (1.2 %) 0.1770
Reoperations
Femoral Neck Fracture 1 (0.8 %) 0 (0 %) 0.1556
Late IT Fracture 0 (0 %) 1 (0.4 %) 0.4777
Fascial Healing Defect 0 (0 %) 1 (0.5 %) 0.4777
TOTAL REOPERATIONS 1 (0.8 %) 2 (0.8 %) 1.000
Table 7 Failures Occurring before 2 Years Postoperatively
Type Group 1 Group 2 P-value
# Cases 121 242 –
Acetabular Failures
Failure of Acetabular Ingrowth 5 (4.1 %) 0 (0 %) 0.0015*
Acetabular Component Shift 0 (0 %) 1 (0.4 %) 0.4777
Femoral Failures
Femoral Neck Fracture 1 (0.8 %) 1 (0.4 %) 0.6171
Femoral Head Collapse 2 (1.7 %) 0 (0 %) 0.0444*
TOTAL FAILURES 8 (6.6 %) 2 (0.8 %) 0.0015*
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Fig. 6 Kaplan-Meier Implant Survivorship Curves, Sorted by Failure Type. Kaplan-Meier survivorship curves for pre-2008 (Group 1) resurfacing
procedures on dysplasia patients, categorized by failure type. Markers at the bottom of a step represent failure while markers at the top of steps
represent censored deaths unrelated to the patient’s hip surgery
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[3, 4, 8–13, 42, 43]. However, HRA remains a
technically-demanding procedure, is seldom taught in
residency programs, and is stigmatized by concerns
that include metal ion levels and implant survivor-
ship. Published tabulations of registry data indicate
that some surgeons have difficulty achieving implant
survivorship results comparable to those of stemmed
THA procedures [44]. However, a growing body of
literature now indicates that surgeons experienced at
resurfacing can achieve favorable implant survivor-
ship, especially in men [5, 35, 45]. We have extended
this observation to include women, specifically those
with developmental dysplasia. It is our expectation
that surgeons striving for expertise at HRA will in-
corporate the interventions described here in order to
offer the functional advantages of HRA to additional
patient populations. We await the experiences of
others as well as the longer-term follow-up results on
our own patients with great interest.
We conclude that:
 With sufficient experience, hip resurfacing
arthroplasty (HRA) can be performed with a success
rate that compares favorably to that of standard
stemmed total hip arthroplasty in dysplasia patients
(99 % 7-year survivorship).
 Dislocations (0.5 %) and revisions for instability
(0 %) are rare when HRA is used in high-risk (for in-
stability) dysplasia patients.
 Adverse wear related failures (AWRF) can be
completely eliminated, and optimal ion levels can
routinely be achieved in high-risk (for AWRF)
dysplasia patients if the Relative Acetabular Inclin-
ation Limit (RAIL) is observed.
 The RAIL can be achieved in a high percentage of
cases (99 %) when a normalized intraoperative x-ray
technique is used.
 Failure of acetabular component fixation can be
avoided (0 %) if an acetabular component with a
supplemental fixation option is selectively (5 %)
employed.
 Early femoral failures can be reduced when a
comprehensive bone management protocol is
followed.
 Uncemented femoral components are highly
successful, but we do not have the data to show if
the lower rate of femoral complications observed
can be assigned to them.
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Millis et al. Bernese
Osteotomy




Adelani et al. Revision THA -Varies- 1996–2006 <55 years old 103 66 % 6.7 6.7 69 %
Current Study Group 1 HRA Corin Hybrid,
Biomet ReCap™ Hybrid




Current Study Group 2 HRA Biomet ReCap™ Uncemented 2008–2013 Dysplasia 242 74 % 2.6 7 99 %
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